IMPACT OF ROUX-EN-Y GASTRIC BYPASS SURGERY (RYGB) ON METABOLIC SYNDROME COMPONENTS AND ON THE USE OF ASSOCIATED DRUGS IN OBESE PATIENTS.
BACKGROUND
The prevalence of obesity and metabolic syndrome is increasing worldwide and both behavior modification and drug therapy have low adherence. Gastric bypass has shown effective results in both reducing weight and improving comorbidities.


OBJECTIVE
To evaluate the impact of Roux-en-Y Gastric Bypass Surgery (RYGB) on both metabolic syndrome components and the use of associated drugs in obese patients.


METHODS
Historical cohort of patients subjected to Roux-en-Y Gastric Bypass Surgery (RYGB) between January 2007 and March 2014 in a private clinic. The sample consisted of 273 obese class II and III individuals, 86.4% of whom were female, with age ≥20 years, followed up for 2 months after surgery. Sociodemographic, anthropometric, biochemical, clinical, and drug-use data were collected from patients' medical records.


RESULTS
Significant differences were found in weight, body mass index and waist circumference, after 60 postoperative days. Components for metabolic syndrome diagnosis (hypertension P=0.001; hyperglycemia P<0.001; hypertriglyceridemia P=0.006) were reduced after 60 days of postoperative, with the exception HDL-c (P=0.083). There was a significant reduction in the use of antihypertensive (P<0.001), hypoglycemic (P=0.013), lipid lowering (P<0.001), and antiobesity (P=0.010) drugs and increased use of gastroprotective drugs, vitamins, and minerals (P<0.001) after 60 postoperative days.


CONCLUSIONS
Patients subjected to Roux-en-Y Gastric Bypass Surgery exhibited both weight loss and significant improvement not only in metabolic syndrome components (except for HDL-c) but in the use of drugs associated with obesity and metabolic syndrome.
Programa de Pós-Graduação em Gerontologia Biomédica do Instituto de Geriatria e Gerontologia da Pontifícia Universidade Católica do Rio Grande do Sul (IGG-PUCRS), Porto Alegre, RS, Brazil.
Vilma Maria
VM
Junges
Centro Integrado de Tratamento da Obesidade (CINTRO), Porto Alegre, RS, Brazil.
Jarbas Marinho
JM
Cavalheiro
Centro Integrado de Tratamento da Obesidade (CINTRO), Porto Alegre, RS, Brazil.
Eliana Franzoi
EF
Fam
Programa de Pós-Graduação em Gerontologia Biomédica do Instituto de Geriatria e Gerontologia da Pontifícia Universidade Católica do Rio Grande do Sul (IGG-PUCRS), Porto Alegre, RS, Brazil.
Vera Elizabeth
VE
Closs
Faculdade de Matemática, Departamento de Estatística, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS) e Instituto de Matemática da Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.
João Feliz
JF
Moraes
Programa de Pós-Graduação em Gerontologia Biomédica do Instituto de Geriatria e Gerontologia da Pontifícia Universidade Católica do Rio Grande do Sul (IGG-PUCRS), Porto Alegre, RS, Brazil.
Maria Gabriela
MG
Gottlieb
D000328:Adult; D000368:Aged; D019440:Anti-Obesity Agents / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D015331:Cohort Studies; D005260:Female; D015390:Gastric Bypass; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications* / Q000188:drug therapy*; D008875:Middle Aged; D009767:Obesity, Morbid / Q000150:complications / Q000601:surgery*; D012189:Retrospective Studies; D012959:Socioeconomic Factors
D019440:Anti-Obesity Agents; D000959:Antihypertensive Agents; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents